GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about SELECT — 24 comments in the full submission. View in context.
330
c/trialwatch·submitted 1 year ago by u/rohan_steiner

why does nobody talk about SELECT

Paperbranch of 8 comments

Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. The discontinuation numbers were the most useful thing in the paper for me and they were in…

Read the full submission and all 24 comments →

This branch

8 comments, started 1 year ago
u/ahmed_iyer19 points·1 year ago

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

replysharereportpermalink
u/trialwatch_theoMOD11 points·1 year ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/rohan_steinerOP6 points·1 year ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/nightowl_injector0 points·1 year ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

replysharereportpermalink
u/rohan_steinerOP1 point·1 year ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/anders_kuusela22 points·1 year ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/week_four_wall-13 points·1 year ago

Which trial, and which arm?

replysharereportpermalink
u/sofia_wikstrom9 points·1 year ago

Same. A press release is a claim about a result; the publication is the result.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.